Filing Details

Accession Number:
0001209191-19-044837
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-06 16:43:29
Reporting Period:
2019-08-05
Accepted Time:
2019-08-06 16:43:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1661567 Michael Parini 50 Northern Avenue
Boston MA 02210
Evp, Cl&Ao No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-08-05 2,330 $86.52 37,333 No 4 M Direct
Common Stock Disposition 2019-08-05 700 $174.74 36,633 No 4 S Direct
Common Stock Disposition 2019-08-05 1,630 $175.51 35,003 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2019-08-05 2,330 $0.00 2,330 $86.52
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
13,980 2027-02-02 No 4 M Direct
Footnotes
  1. Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $174.74 (range $174.19 to $175.01).
  3. Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $175.51 (range $175.07 to $176.04).
  5. The option vests in 16 quarterly installments from 2/3/2017.